Singapore, July 6 -- China-based Sanyou Biopharmaceutical and Guangzhou Baiyunshan Xihe Health Pharmaceutical have jointly announced the official signing of a strategic cooperation agreement. This partnership will focus on the co-development of novel radiopharmaceuticals and radiodiagnostic products, aiming to integrate their respective core strengths in AI-driven innovative drug molecule discovery and the full industrial value chain of nuclear medicine.

Together, the two parties seek to build an end-to-end innovation chain spanning from target molecule discovery to clinical translation of radiopharmaceuticals, delivering more transformative solutions for precision oncology diagnosis and therapy.

The development of radiopharmaceuticals ...